Should we use proton pump inhibitors as an add-on treatment in hereditary hemochromatosis?

References (1)

1. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A. The discovery of the new haemochromatosis gene. 1996. J Hepatol 2003; 38: 704-9. [CrossRef] 2. Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis, and treatment. Am J Hematol 2006; 81: 202-9. [CrossRef] 3. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship be-tween iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997; 25: 162-6. [CrossRef] 4. Fracanzani AL, Fargion S, Romano R, et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology 1995; 22: 1127-31. [CrossRef] 5. Simon M, Bourel M, Genetet B, Fauchet R. Idiopathic hemochroma-tosis. Demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 1977; 297: 1017-21. [CrossRef] 6. Adams PC, Barton JC. How I treat hemochromatosis. Blood 2010; 116: 317-25. [CrossRef] 7. Vanclooster A, van Deursen C, Jaspers R, Cassiman D, Koek G. Pro-ton pump ınhibitors decrease phlebotomy need in hfe hemochroma-tosis: double-blind randomized placebo-controlled trial. Gastroenter-ology 2017; 153: 678-80 e2. 8. Adams PC. The Irony of Long-term Acid Suppression. Gastroenter-ology 2017; 153: 637-8. [CrossRef]